GENFIT Reveals Encouraging Preclinical Findings on NTZ/G1090N for ACLF Treatment

GENFIT, a biopharmaceutical firm focused on rare liver diseases, has presented new preclinical data on their investigational drug G1090N at The Liver Meeting® 2025. This development targets Acute-on-Chronic Liver Failure (ACLF), marked by multiple organ dysfunctions and high mortality. The data shows significant promise in reducing systemic inflammation and improving organ function in ACLF models.

Development of G1090N is supported by results showing NTZ's efficacy when administered following an ACLF trigger. Additionally, phase 1 safety data on healthy volunteers and initial efficacy results from ex-vivo analyses are anticipated by the end of 2025.

Positive outcomes from these studies could lead to enhanced clinical development, addressing crucial needs in ACLF treatment. With its ongoing commitment, GENFIT aims to advance therapeutic options for liver disease patients worldwide.